Biotech and Pharma Industry News | BioPharma Dive
BioPharma Dive provides news and analysis for biotech and biopharmaceutical executives. We cover topics like clinical trials, drug discovery and development, pharma marketing, FDA approvals and regulations, and more.
The golden era of GLP-1 drugs: Where we are and what comes next
Sep 23, 2024 · Glucagon-like peptide 1 (GLP-1) receptor agonists (RAs) are entero-pancreatic hormone-based treatments first approved in 2005 for type 2 diabetes (T2D). They are now commonly prescribed for weight loss and reduction of atherosclerotic cardiovascular (CV) risk in patients with T2D. The health benefits and market success of GLP-1 drugs are a hot ...
Meso Scale Discovery (MSD): An immunoassay platform with …
Feb 22, 2022 · ADVANTAGES. Sensitivity, Range and Ease-of-Use: In comparison to a conventional ELISA, MSD has higher sensitivity (LLOD 0.1-1.4 pg/mL) and a larger dynamic detection range (0.1-10 pg/mL).In addition, MSD has an efficient low volume sampling (1-25 μ L) and minimized matrix effect aiding in simultaneous multiplex detection with high precision. . Furthermore, MSD has simpler protocols, reduced ...
Biotech M&A has plateaued. Track the deals that are happening …
Oct 28, 2024 · The state of biosimilars in 2024. The arrival of lookalike competition to AbbVie’s Humira in the U.S. presents an opportunity, and a test, for the cost-saving potential of biosimilars. BioPharma Dive is tracking M&A activity below. The database, which shows drugmaker buyouts that have happened since 2018 and were valued at $50 million or more ...
10 clinical trials to watch in the first half of 2024
Jan 2, 2024 · Moderna and Pfizer both reported promising results in early testing last fall and have moved on to late-stage studies. Moderna appears positioned to get to the finish line first. Results from its Phase 3 trial could be coming in the first half of this year, according to a federal database. — Delilah Alvarado.
Pharma News | BioPharma Dive
Nov 6, 2024 · GSK invests $800M in manufacturing; Amgen sets small discount for Eylea biosimilar. The British pharma is making what it calls its largest U.S. manufacturing investment. Elsewhere, Roche and Dyno expanded their alliance to create better viral vectors for use in gene therapy. By BioPharma Dive staff • Oct. 25, 2024.
Biotech News - BioPharma Dive
6 days ago · A new biotech, built around protein design, springs from David Baker’s lab. Archon Biosciences, co-founded by the winner of the 2024 Nobel Prize in Chemistry, emerged from stealth Wednesday with $20 million in seed capital. By Gwendolyn Wu • Oct. 30, 2024.
Novartis wins FDA approval for new heart drug, but faces uphill …
Dec 22, 2021 · Novartis priced Leqvio at $3,250 per dose for U.S. sale, meaning the first year of treatment will cost $9,750 and subsequent years $6,500. That’s slightly higher than the $5,400-per-year price that the Institute for Clinical and Economic Review, a watchdog group on drug costs, said would be cost effective for Leqvio when used broadly, but ...
The biopharma industry outlook on 2024: Guarded optimism for a …
Published Jan. 16, 2024. Ned Pagliarulo Lead Editor. Brian Tucker / BioPharma Dive. Guarded optimism seems to be the mood of the biopharmaceutical industry to start 2024. Last year brought a stock market slide and layoffs for more than 150 drug companies. Financial and regulatory headwinds, like the March collapse of Silicon Valley Bank and a ...
A biotech startup gives Merck its next shot at treating Alzheimer’s
Published Aug. 9, 2022. Gwendolyn Wu Reporter. Merck & Co. will acquire an early-stage Alzheimer’s disease treatment from Boston-based Cerevance, which focuses on central nervous system diseases. Kena Betancur via Getty Images. Merck & Co. is buying into another Alzheimer’s drug, this time through a backloaded deal with Boston-based Cerevance.